Baker Bros. Advisors OPTEY Position
ExitedBaker Bros. Advisors exited their position in Opthea Ltd (OPTEY) in Q4 2025, after holding the stock for 12 quarters.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
Short Interest
0.4%
0.0 days to cover
Baker Bros. Advisors OPTEY Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Exited | 0 | -2,087,320 | $0 |
| Q3 2025 | Held | 2,087,320 | — | $0 |
| Q2 2025 | Held | 2,087,320 | — | $0 |
| Q1 2025 | Decreased | 2,087,320 | -86,302 | $0 |
| Q4 2024 | Held | 2,173,622 | — | $8.5M |
| Q3 2024 | Held | 2,173,622 | — | $8.8M |
| Q2 2024 | Decreased | 2,173,622 | -4,204 | $4.2M |
| Q1 2024 | Decreased | 2,177,826 | -410,819 | $9.0M |
| Q4 2023 | Decreased | 2,588,645 | -102,246 | $7.6M |
| Q3 2023 | Decreased | 2,690,891 | -500 | $4.7M |
| Q2 2023 | Held | 2,691,391 | — | $7.5M |
| Q1 2023 | New | 2,691,391 | +2,691,391 | $10.6M |
Frequently Asked Questions
Does Baker Bros. Advisors own OPTEY?
No. Baker Bros. Advisors exited their position in Opthea Ltd (OPTEY) in Q4 2025. They previously held the stock for 12 quarters.
How many hedge funds own OPTEY?
Based on the 20 specialist biotech hedge funds tracked by BiotechEdge, no tracked fund currently holds an active position in OPTEY.
When did Baker Bros. Advisors first buy OPTEY?
Baker Bros. Advisors's position in OPTEY was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's OPTEY position increasing or decreasing?
Baker Bros. Advisors completely exited their OPTEY position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
OPTEYCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →